Small-molecule inhibitors of the mTORC2 kinase (torkinibs) have shown efficacy in early clinical trials. However, the torkinibs under study also inhibit the other mTOR-containing complex mTORC1. While mTORC1/mTORC2 combined inhibition may be beneficial in cancer cells, recent reports describe compensatory cell survival upon mTORC1 inhibition due to loss of negative feedback on PI3K, increased autophagy, and increased macropinocytosis. Genetic models suggest that selective mTORC2 inhibition would be effective in breast cancers, but the lack of selective small-molecule inhibitors of mTORC2 have precluded testing of this hypothesis to date. Here we report the engineering of a nanoparticle-based RNAi therapeutic that can effectively silence the mTORC2 obligate cofactor Rictor. Nanoparticle-based Rictor ablation in HER2-amplified breast tumors was achieved following intratumoral and intravenous delivery, decreasing Akt phosphorylation and increasing tumor cell killing. Selective mTORC2 inhibition , combined with the HER2 inhibitor lapatinib, decreased the growth of HER2-amplified breast cancers to a greater extent than either agent alone, suggesting that mTORC2 promotes lapatinib resistance, but is overcome by mTORC2 inhibition. Importantly, selective mTORC2 inhibition was effective in a triple-negative breast cancer (TNBC) model, decreasing Akt phosphorylation and tumor growth, consistent with our findings that RICTOR mRNA correlates with worse outcome in patients with basal-like TNBC. Together, our results offer preclinical validation of a novel RNAi delivery platform for therapeutic gene ablation in breast cancer, and they show that mTORC2-selective targeting is feasible and efficacious in this disease setting. This study describes a nanomedicine to effectively inhibit the growth regulatory kinase mTORC2 in a preclinical model of breast cancer, targeting an important pathogenic enzyme in that setting that has been undruggable to date. .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882532 | PMC |
| http://dx.doi.org/10.1158/0008-5472.CAN-17-2388 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Small Molecule Modulator of the mTORC2 Pathway Discovered from a DEL Library Designed to Bind to Pleckstrin Homology Domains.
ACS Chem Biol
December 2024
Department of Organic Chemistry, Faculty of Sciences, University of Geneva, Geneva 12004, Switzerland.
Pleckstrin homology (PH) domains are structural motifs critical for cellular processes, such as signal transduction and cytoskeletal organization. Due to their involvement in various diseases, PH domains are promising therapeutic targets, yet their highly charged and hydrophobic binding sites are not ideal for traditional small drugs. In this study, we designed a DNA-encoded library (DEL) mimicking phospholipids to identify novel modulators targeting PH domains with uncharted chemical properties.
View Article and Find Full Text PDFArticle Synopsis
- Advances in colorectal cancer (CRC) treatment face challenges due to fast tumor spread and screening issues, especially for early-onset CRC, highlighting the need for better therapies.
- The Rictor-mTORC2-AKT pathway is critical in promoting metastasis, and selective inhibitors targeting mTORC2, like Veratridine (VTD), show promise in reducing tumor growth and metastasis.
- VTD acts by destabilizing Rictor, leading to decreased cancer stem cell populations and aggressive tumor behaviors in CRC, offering a new potential approach to treatment.
Protection by selective mTORC2 inhibition of Zymosan-induced hypotension and systemic inflammation mediated via IKKα/IκB-α/NF-κB activation.
Prostaglandins Other Lipid Mediat
December 2024
Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Turkey. Electronic address:
Non-septic shock is a serious condition leading to multiple organ dysfunction. Although targeting the mammalian target of the rapamycin complex 1 (mTORC1) signaling pathway exerts potent anti-inflammatory activity, little is known about mTORC2's contribution to non-septic shock. Thus, our research aims to investigate mTORC2's contribution and associated changes of IκB kinase (IKKα)/inhibitor κB (IκB-α)/nuclear factor-ĸB (NF-κB) pathway on Zymosan (ZYM)-induced non-septic rat model using the novel mTORC2 selective inhibitor JR-AB2-011.
View Article and Find Full Text PDFFunctional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib.
Cancers (Basel)
October 2024
Celcuity, Inc., 16305 36th Ave N, Suite 100, Minneapolis, MN 55446, USA.
: The PI3K/AKT/mTOR (PAM) pathway is frequently activated in gynecological cancers. Many PAM inhibitors selectively target single PAM pathway nodes, which can lead to reduced efficacy and increased drug resistance. To address these limitations, multiple PAM pathway nodes may need to be inhibited.
View Article and Find Full Text PDFmTORC2 inhibition by JR-AB2-011 improves IL-1β-induced inflammation, catabolic response, and apoptosis in human chondrocytes through IκB-α/NF-κB p65.
Cell Mol Biol (Noisy-le-grand)
October 2024
Department of Pharmacology, Faculty of Pharmacy, Mersin University, Mersin, Turkey.
Article Synopsis
- * The study investigates how mTORC2 influences inflammatory responses in human chondrocytes, focusing on the Akt and NF-κB signaling pathways when treated with IL-1β.
- * Key findings indicate that inhibiting mTORC2 with JR-AB2-011 can block inflammation and cell death caused by IL-1β, suggesting it may be a promising therapeutic target for OA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!